Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Clinical features of neuroendocrine prostate cancer.

Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento O, Nanus DM, Tagawa ST, Ballman KV, Beltran H.

Eur J Cancer. 2019 Sep 13;121:7-18. doi: 10.1016/j.ejca.2019.08.011. [Epub ahead of print]

PMID:
31525487
2.

Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.

Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JM, Nanus DM, Pisapia DJ, Rao RA, Robinson BD, Rubin MA, Elemento O, Sboner A, Shah MA, Song W.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00400. Epub 2019 Jul 31.

3.

Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues.

Persi E, Prandi D, Wolf YI, Pozniak Y, Barnabas GD, Levanon K, Barshack I, Barbieri C, Gasperini P, Beltran H, Faltas BM, Rubin MA, Geiger T, Koonin EV, Demichelis F, Horn D.

Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16987-16996. doi: 10.1073/pnas.1908790116. Epub 2019 Aug 6.

PMID:
31387980
4.

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.

Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J, Tagawa ST, Nanus DM, Beltran H, Molina AM, Khani F, Miguel Mosquera J, Xylinas E, Shariat SF, Scherr DS, Rubin MA, Lerner SP, Matin SF, Elemento O, Faltas BM.

Nat Commun. 2019 Jul 5;10(1):2977. doi: 10.1038/s41467-019-10873-y.

5.

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JM, Scherr DS, Sboner A, Tagawa ST, Molina AM, Elemento O, Nanus DM, Faltas BM.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):194-200. doi: 10.6004/jnccn.2018.7264.

PMID:
30865916
6.

Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma.

Shohdy KS, Vlachostergios PJ, Abdel-Malek RR, Faltas BM.

Expert Opin Ther Targets. 2019 Feb;23(2):83-86. doi: 10.1080/14728222.2019.1559828. Epub 2018 Dec 17. No abstract available. Erratum in: Expert Opin Ther Targets. 2019 Jul;23(7):645.

PMID:
30558440
7.

The molecular limitations of biomarker research in bladder cancer.

Vlachostergios PJ, Faltas BM.

World J Urol. 2019 May;37(5):837-848. doi: 10.1007/s00345-018-2462-9. Epub 2018 Aug 31.

PMID:
30171455
8.

Treatment resistance in urothelial carcinoma: an evolutionary perspective.

Vlachostergios PJ, Faltas BM.

Nat Rev Clin Oncol. 2018 Aug;15(8):495-509. doi: 10.1038/s41571-018-0026-y. Review.

PMID:
29720713
9.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P.

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

10.

Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes.

Faltas BM, Gennarelli RL, Elkin E, Nguyen DP, Hu J, Tagawa ST.

Urol Oncol. 2018 Jan;36(1):9.e11-9.e17. doi: 10.1016/j.urolonc.2017.09.009. Epub 2017 Oct 5.

11.

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA.

Cancer Discov. 2017 May;7(5):462-477. doi: 10.1158/2159-8290.CD-16-1154. Epub 2017 Mar 22.

12.

Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer.

Faltas BM, Tagawa ST.

Lancet. 2017 Jan 7;389(10064):6-7. doi: 10.1016/S0140-6736(16)32516-8. Epub 2016 Dec 8. No abstract available.

PMID:
27939401
13.

Clonal evolution of chemotherapy-resistant urothelial carcinoma.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, Sboner A, Beltran H, Demichelis F, Rubin MA.

Nat Genet. 2016 Dec;48(12):1490-1499. doi: 10.1038/ng.3692. Epub 2016 Oct 17.

14.

Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Alme AK, Karir BS, Faltas BM, Drake CG.

Urol Oncol. 2016 Apr;34(4):171-81. doi: 10.1016/j.urolonc.2016.01.006. Epub 2016 Feb 28. Review.

15.

Radical Cystectomy for Bladder Cancer in Patients With and Without a History of Pelvic Irradiation: Survival Outcomes and Diversion-related Complications.

Nguyen DP, Al Hussein Al Awamlh B, Faltas BM, O'Malley P, Ayangbesan A, Inoyatov IM, Scherr DS.

Urology. 2015 Jul;86(1):99-106. doi: 10.1016/j.urology.2015.02.061.

PMID:
26142590
16.

Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer.

Nguyen DP, Al Hussein Al Awamlh B, Wu X, O'Malley P, Inoyatov IM, Ayangbesan A, Faltas BM, Christos PJ, Scherr DS.

Eur Urol. 2015 Sep;68(3):399-405. doi: 10.1016/j.eururo.2015.02.003. Epub 2015 Feb 20.

17.

Novel molecular targets for urothelial carcinoma.

Faltas BM, Karir BS, Tagawa ST, Rosenberg JE.

Expert Opin Ther Targets. 2015 Apr;19(4):515-25. doi: 10.1517/14728222.2014.987662. Epub 2015 Jan 30. Review.

Supplemental Content

Loading ...
Support Center